LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. announced today that its first patents have been granted by the U.S. Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s deuterium chemistry platform. U.S. Patents 7,514,068 and 7,528,131 specifically claim deuterium analogs of rimonabant and mosapride, respectively. In addition to these patents, Concert has over 100 pending U.S. patent applications and corresponding applications worldwide.
